Clinical Trial Update: A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating INCB57643 in combination with ruxolitinib for myelofibrosis in JAK inhibitor-naïve patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• INCB57643
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myelofibrosis | Phase 2 | Status: WITHDRAWN